StockNews.AI
ABVX
StockNews.AI
2 days

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

1. Abivax schedules a KOL webcast featuring Dr. David Rubin. 2. Webcast will discuss the ABTECT Phase 3 trial for ulcerative colitis. 3. Event focuses on obefazimod's potential to meet critical UC needs. 4. Investors can join a live Q&A with management post-presentation.

4 mins saved
Full Article

FAQ

Why Bullish?

The event spotlights pivotal Phase 3 trial details with an expert endorsement, historically boosting investor confidence in similar biotech setups.

How important is it?

Direct communication on trial progress and KOL insights carries a substantial chance to positively affect the stock in the near term.

Why Short Term?

Immediate market reactions are expected as investors interpret the expert insights, similar to past webcast catalysts.

Related Companies

TAKJNJ
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax’s Pivotal ABTECT Phase 3 Trial PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET). The webcast will feature Professor David T. Rubin, MD, Chief of the Section of Gastroenterology, Hepatology, and Nutrition and Director of the Inflammatory Bowel Disease Center at The University of Chicago. Dr. Rubin will provide expert insights into the evolving treatment landscape for ulcerative colitis (UC) and discuss expectations for Abivax’s ABTECT Phase 3 trial evaluating obefazimod in adults with moderately to severely active UC. He will also explore obefazimod’s potential to address critical unmet medical needs in UC treatment. Following the presentation, attendees will have the opportunity to participate in a live Q&A session with Dr. Rubin and Abivax’s management team. Event Details: Date: Monday, March 17, 2025 Time: 9:00 a.m. EDT | 2:00 p.m. CET Format: Virtual webcast Registration Details: To register for the webcast and access further event details, please click on this link https://lifescievents.com/event/abivax-3/.   About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX. Contact: Patrick MalloySVP, Investor Relations Abivax SApatrick.malloy@abivax.com+1 847 987 4878

Related News